By Sabela Ojea
Kyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer.
The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he most recently served as the head of clinical development for breast cancer treatment imlunestrant.
As part of this appointment, Kyverna's current president of research and development, Dominic Borie, will move to a new role as strategic advisor to Chief Executive Officer Warner Biddle and the board.
Borie in the past acted as the founding CEO at Kyverna.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
January 21, 2025 17:17 ET (22:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.